Skip to content
Buy This GLP
← Research
Evidence

Can You Take a GLP-1 and an SGLT2 Inhibitor Together?

Some people with type 2 diabetes and cardiovascular risk may be prescribed both. The strength of the evidence depends on the outcome.

Editorial profile: Carla MedinaBuy This GLP Editorial Team5 min read
Composite renal events vs placebocombination0.63SGLT2 inhibitor alone0.71.0Separate estimates against placebo, with 95% confidence intervals

Clinicians can prescribe a GLP-1 and an SGLT2 inhibitor together. The American Diabetes Association says the combination may be considered for some people with type 2 diabetes who have established atherosclerotic cardiovascular disease or multiple risk factors. The recommendation applies to medicines with demonstrated cardiovascular benefit [4].

What a randomized combination trial found

Our comparison of GLP-1 and SGLT2 medicines explains why both classes are used in type 2 diabetes. DURATION-8 randomly assigned 695 adults whose blood sugar remained high on metformin to exenatide plus dapagliflozin or either medicine alone. At 28 weeks, HbA1c fell 0.4 percentage points more with the combination than with exenatide alone and 0.6 points more than with dapagliflozin alone [2].

Blood sugar was the trial’s primary outcome. The study was designed to answer a different question from whether taking both medicines prevents more heart attacks or kidney complications over time [2].

What the evidence says about heart and kidney outcomes

Studies of GLP-1 medicines and kidney disease provide context for what individual medicines can do. A separate review pooled 16 randomized trials to estimate outcomes with both medicines. Much of the combination evidence came from subgroups based on medicines participants were already taking. The original trials generally did not randomly assign that background treatment [1].

For the composite kidney outcome, the estimated risk ratio versus placebo was 0.63 with the combination (95% confidence interval 0.41–0.97) and 0.70 with an SGLT2 inhibitor alone (0.61–0.79). These two placebo comparisons do not establish an added kidney benefit from taking both [1].

What happened when patients filled prescriptions

The guide to filling a GLP-1 prescription explains why a prescription and a fill are measured separately. The PRECIDENTD feasibility study randomly assigned 173 insured adults with type 2 diabetes and cardiovascular disease or high cardiovascular risk to one of the two classes or both. By four months, 84% assigned one medicine filled it and 53% assigned both filled both. Over the full follow-up, which had a median of 10 months, those figures were 87% and 68%. This report examined access and use, rather than long-term heart or kidney outcomes [3].

What to discuss with the prescriber

Ask what each medicine is intended to treat and what monitoring you need. For example, the U.S. label for empagliflozin, an SGLT2 inhibitor, warns about dehydration from fluid loss and ketoacidosis. It also warns that taking empagliflozin with insulin can increase the risk of low blood sugar[5].

Frequently asked

Can you take a GLP-1 and an SGLT2 inhibitor together?
Yes, when prescribed together. The ADA says this combination may be considered in some people with type 2 diabetes and established atherosclerotic cardiovascular disease or multiple risk factors.
Does taking both work better than taking one?
In DURATION-8, combining exenatide and dapagliflozin lowered HbA1c more than either alone. The size of any added benefit for heart and kidney outcomes remains uncertain.

Sources

  1. [1] Banerjee M, et al. (2026). Combined use of SGLT2 inhibitor and GLP-1 receptor agonist versus either monotherapy for cardiorenal Outcomes: an exploratory network meta-analysis of 16 randomized trials Endocrine. PMID 42616235
  2. [2] Frías JP, Guja C, Hardy E, et al. (2016). Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8) The Lancet Diabetes & Endocrinology. PMID 27651331
  3. [3] Wexler DJ, Mayberry LS, Nelson LA, Lema-Driscoll J, Flores LC, Malloy M (2026). Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial American Heart Journal. PMID 41456635
  4. [4] American Diabetes Association Professional Practice Committee (2026). Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026, recommendation 10.40d Diabetes Care. Source
  5. [5] Boehringer Ingelheim Pharmaceuticals (2026). Jardiance prescribing information, Warnings and Precautions DailyMed, U.S. National Library of Medicine. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence